Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.

Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.

Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.

Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.

Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.

Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.

Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, resulting in increased cartilage formation. When hyaluronic acid is administered in addition to FGF18, the effects on chondrocyte proliferation and production of matrix were found to be greater than administration of FGF18 or hyaluronic acid alone.

Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.

Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.

Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.

Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.

Abstract: Disclosed are soluble Fc?RIA polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble Fc?RIA polypeptides.

Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.

Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, resulting in increased cartilage formation. When hyaluronic acid is administered in addition to FGF18, the effects on chondrocyte proliferation and production of matrix were found to be greater than administration of FGF18 or hyaluronic acid alone.

Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, resulting in increased cartilage formation. When hyaluronic acid is administered in addition to FGF18, the effects on chondrocyte proliferation and production of matrix were found to be greater than administration of FGF18 or hyaluronic acid alone.

Abstract: The present invention relates to polynucleotide and polypeptide molecules for zfsta2, a novel member of the follistatin family. The polypeptides, and polynucleotides encoding them are useful for binding to members of the TGF-&bgr; family and mediating central nervous system, reproductive, hematopoietic and bone-related activities. The present invention also includes antibodies to the zfsta2 polypeptides.

Abstract: The present invention relates to zpep10 polypeptides and polynucleotides encoding the same. Zpep10 polypeptide is a testis-specific membrane glycoprotein. Zpep10 polypeptides would be useful for modulating spermatogenesis and egg-sperm interaction and would be useful to study or modulate these functions in in vitro or in vivo systems. The present invention also includes antibodies to the zpep10 polypeptides.

Abstract: The present invention relates to zpep10 polypeptides and polynucleotides encoding the same. Zpep10 polypeptide is a testis-specific membrane glycoprotein. Zpep10 polypeptides would be useful for modulating spermatogenesis and egg-sperm interaction and would be useful to study or modulate these functions in in vitro or in vivo systems. The present invention also includes antibodies to the zpep10 polypeptides.

Abstract: The present invention relates to polynucleotide and polypeptide molecules for zfsta2, a novel member of the follistatin family. The polypeptides, and polynucleotides encoding them are useful for binding to members of the TGF-&bgr; family and mediating central nervous system, reproductive, hematopoietic and bone-related activities. The present invention also includes antibodies to the zfsta2 polypeptides.

Abstract: The present invention relates to zpep10 polypeptides and polynucleotides encoding the same. Zpep10 polypeptide is a testis-specific membrane glycoprotein. Zpep10 polypeptides would be useful for modulating spermatogenesis and egg-sperm interaction and would be useful to study or modulate these functions in in vitro or in vivo systems. The present invention also includes antibodies to the zpep10 polypeptides.